Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD)

PHASE4UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Major Depressive Disorder (MDD)
Interventions
DRUG

Agomelatine

Participants who are randomly assigned to the agomelatine group will be treated with agomelatine oral tablets for twelve weeks. Participants will begin their agomelatine treatment at 25mg/day dosage, increasing to 50mg/day as clinically indicated.

DRUG

Escitalopram

Participants who are randomly assigned to the escitalopram group will be treated with escitalopram oral tablets for twelve weeks. Participants will begin their escitalopram treatment at 10mg/day dosage, increasing to 20mg/day as clinically indicated.

Trial Locations (3)

3004

Alfred and Baker Medical Unit - Alfred Hospital, Melbourne

Baker IDI Heart & Diabetes Institute, Melbourne

3168

Monash Medical Centre - Monash Health, Clayton

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Servier Laboratories (Australia) Pty Ltd

UNKNOWN

collaborator

The Alfred

OTHER

collaborator

Monash Medical Centre

OTHER

lead

Baker Heart and Diabetes Institute

OTHER